Literature DB >> 32706893

Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.

Korsuk Sirinukunwattana1,2,3,4, Alan Aberdeen2, Helen Theissen1,3, Nikolaos Sousos5,6, Bethan Psaila4,5,6, Adam J Mead4,5,6, Gareth D H Turner7,8, Gabrielle Rees7, Jens Rittscher1,2,3,4,9, Daniel Royston7,8.   

Abstract

Accurate diagnosis and classification of myeloproliferative neoplasms (MPNs) requires integration of clinical, morphological, and genetic findings. Despite major advances in our understanding of the molecular and genetic basis of MPNs, the morphological assessment of bone marrow trephines (BMT) is critical in differentiating MPN subtypes and their reactive mimics. However, morphological assessment is heavily constrained by a reliance on subjective, qualitative, and poorly reproducible criteria. To improve the morphological assessment of MPNs, we have developed a machine learning approach for the automated identification, quantitative analysis, and abstract representation of megakaryocyte features using reactive/nonneoplastic BMT samples (n = 43) and those from patients with established diagnoses of essential thrombocythemia (n = 45), polycythemia vera (n = 18), or myelofibrosis (n = 25). We describe the application of an automated workflow for the identification and delineation of relevant histological features from routinely prepared BMTs. Subsequent analysis enabled the tissue diagnosis of MPN with a high predictive accuracy (area under the curve = 0.95) and revealed clear evidence of the potential to discriminate between important MPN subtypes. Our method of visually representing abstracted megakaryocyte features in the context of analyzed patient cohorts facilitates the interpretation and monitoring of samples in a manner that is beyond conventional approaches. The automated BMT phenotyping approach described here has significant potential as an adjunct to standard genetic and molecular testing in established or suspected MPN patients, either as part of the routine diagnostic pathway or in the assessment of disease progression/response to treatment.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32706893      PMCID: PMC7391156          DOI: 10.1182/bloodadvances.2020002230

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  29 in total

1.  WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Mar García; Fina Climent; Francesc García-Pallarols; Anna Angona; Alicia Senín; Carlos Barranco; Luz Martínez-Avilés; Sergio Serrano; Beatriz Bellosillo; Carlos Besses
Journal:  Br J Haematol       Date:  2014-06-24       Impact factor: 6.998

2.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

3.  Equivalence of BCSH and WHO diagnostic criteria for ET.

Authors:  C N Harrison; M F McMullin; A R Green; A J Mead
Journal:  Leukemia       Date:  2017-05-05       Impact factor: 11.528

4.  Myeloproliferative Neoplasms.

Authors:  Jerry L Spivak
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

Review 5.  Heterogeneity in myeloproliferative neoplasms: Causes and consequences.

Authors:  Jennifer O'Sullivan; Adam J Mead
Journal:  Adv Biol Regul       Date:  2018-11-22

Review 6.  Machine learning applications in the diagnosis of leukemia: Current trends and future directions.

Authors:  Haneen T Salah; Ibrahim N Muhsen; Mohamed E Salama; Tarek Owaidah; Shahrukh K Hashmi
Journal:  Int J Lab Hematol       Date:  2019-09-09       Impact factor: 2.877

Review 7.  Emerging Themes in Image Informatics and Molecular Analysis for Digital Pathology.

Authors:  Rohit Bhargava; Anant Madabhushi
Journal:  Annu Rev Biomed Eng       Date:  2016-07-11       Impact factor: 9.590

8.  Digital images and the future of digital pathology.

Authors:  Liron Pantanowitz
Journal:  J Pathol Inform       Date:  2010-08-10

Review 9.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

10.  Deep learning approach to peripheral leukocyte recognition.

Authors:  Qiwei Wang; Shusheng Bi; Minglei Sun; Yuliang Wang; Di Wang; Shaobao Yang
Journal:  PLoS One       Date:  2019-06-25       Impact factor: 3.240

View more
  10 in total

1.  Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering.

Authors:  Pingjun Chen; Siba El Hussein; Fuyong Xing; Muhammad Aminu; Aparajith Kannapiran; John D Hazle; L Jeffrey Medeiros; Ignacio I Wistuba; David Jaffray; Joseph D Khoury; Jia Wu
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

Review 2.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

Review 3.  Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.

Authors:  Daniel Royston; Adam J Mead; Bethan Psaila
Journal:  Hematol Oncol Clin North Am       Date:  2021-04       Impact factor: 3.722

4.  Deep learning-based histopathological segmentation for whole slide images of colorectal cancer in a compressed domain.

Authors:  Hyeongsub Kim; Hongjoon Yoon; Nishant Thakur; Gyoyeon Hwang; Eun Jung Lee; Chulhong Kim; Yosep Chong
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

5.  Self-Organizing Maps for Cellular In Silico Staining and Cell Substate Classification.

Authors:  Edwin Yuan; Magdalena Matusiak; Korsuk Sirinukunwattana; Sushama Varma; Łukasz Kidziński; Robert West
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

Review 6.  A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects.

Authors:  Yousra El Alaoui; Adel Elomri; Marwa Qaraqe; Regina Padmanabhan; Ruba Yasin Taha; Halima El Omri; Abdelfatteh El Omri; Omar Aboumarzouk
Journal:  J Med Internet Res       Date:  2022-07-12       Impact factor: 7.076

7.  Integrating artificial intelligence into haematology training and practice: Opportunities, threats and proposed solutions.

Authors:  Shang Yuin Chai; Amjad Hayat; Gerard Thomas Flaherty
Journal:  Br J Haematol       Date:  2022-07-04       Impact factor: 8.615

Review 8.  The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Authors:  Tanja Belčič Mikič; Tadej Pajič; Samo Zver; Matjaž Sever
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

9.  Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies.

Authors:  Andrea Chatrian; Richard T Colling; Jens Rittscher; Clare Verrill; Lisa Browning; Nasullah Khalid Alham; Korsuk Sirinukunwattana; Stefano Malacrino; Maryam Haghighat; Alan Aberdeen; Amelia Monks; Benjamin Moxley-Wyles; Emad Rakha; David R J Snead
Journal:  Mod Pathol       Date:  2021-05-20       Impact factor: 7.842

Review 10.  How artificial intelligence might disrupt diagnostics in hematology in the near future.

Authors:  Wencke Walter; Claudia Haferlach; Niroshan Nadarajah; Ines Schmidts; Constanze Kühn; Wolfgang Kern; Torsten Haferlach
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.